Effect of latanoprost as adjunctive therapy.
BACKGROUND
Latanoprost may be a useful adjunct in some patients receiving maximum tolerated medical therapy. We report our clinical experience with latanoprost when added to one or two other glaucoma medications.


METHODS
Review of the charts of 53 patients with open-angle glaucoma whose intraocular pressure (IOP) was uncontrolled with one or two glaucoma medications and who had latanoprost added as a second or third drug. Patients whose IOP decreased by 3 mm Hg or more were considered to be responders.


RESULTS
The shortest length of follow-up was 2.3 months (median 5.8 months). Latanoprost was given as a second medication to 35 patients, of whom 22 (63%) responded, with a mean IOP reduction of 6.1 mm Hg (standard deviation [SD] 2.73 mm Hg) (28.7% [SD 12.10%]). Of the 18 patients to whom latanoprost was given as a third medication, 10 (56%) responded, with a mean IOP reduction of 6.3 mm Hg (SD 3.86 mm Hg) (24.5% [SD 10.12%]).


CONCLUSIONS
Latanoprost provides additional IOP reduction in some patients with open-angle glaucoma when added to one or two other glaucoma medications.
DesMarchais
B
B
Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Conn. 06520-8061, USA.
Candal
E
E
Weitzman
M
M
Shields
M B
MB
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018678:Cholinergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D017889:Exfoliation Syndrome / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D018678:Cholinergic Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost